Nivolumab-AVD versus Brentuximab Vedotin-AVD as First-Line Treatment for Advanced-Stage Classical Hodgkin Lymphoma: A Cost-Effectiveness Analysis

Biao Li,1,* Jingjing Yang,1,* Jing Li,2,* Jiajia Huang,1 Zhiming Li1 1Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People’s Republ...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Li B, Yang J, Li J, Huang J, Li Z
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	Dove Medical Press 2026-05-01
Cyfres:	ClinicoEconomics and Outcomes Research
Pynciau:	Classical Hodgkin Lymphoma Nivolumab-AVD brentuximab vedotin-AVD Quality-adjusted life-years Incremental cost‐effectiveness ratio.
Mynediad Ar-lein:	https://www.dovepress.com/nivolumab-avd-versus-brentuximab-vedotin-avd-as-first-line-treatment-f-peer-reviewed-fulltext-article-CEOR
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!